Nuvectis Pharma, Inc. (NVCT)

6.50 -0.25 (-3.70%) At close: 04:00PM EDT

Nuvectis Pharma, Inc.

1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
United States
201 614 3150
https://www.nuvectis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ron Bentsur M.B.A.	Co-Founder, Chairman, CEO & President	1.12M	N/A	1966
Dr. Enrique Poradosu Ph.D.	Co-Founder, Executive VP, Chief Scientific & Business Officer	705.5k	N/A	1967
Mr. Shay Shemesh	Co-Founder, Executive VP, Chief Development & Operations Officer	705.5k	N/A	1984
Mr. Michael Carson CPA	Vice President of Finance	N/A	N/A	1976

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Corporate governance

Nuvectis Pharma, Inc.’s ISS governance QualityScore as of 18 September 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.